CBDMD INC (YCBD)
AMEXHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$0.48-1.12%
Close 2026-09-04 · 1-day change
AMEXHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · YCBD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 14.4% |
Growth built into the price is above our model estimate.
The price assumes 104.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 24 industry peers · Company calendar date is not available
YCBD — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-05-20
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in “
Why it matters: Managing capital spending is key. The company has new financial duties. This is important for stability.
Worry ifManagement has a clear plan. They want to increase spending while handling financial duties.
Less concerning ifNo news or unclear details on capital spending plans.
Why it matters: Improving operating income is key for long-term growth. It shows better cost management.
Supportive ifOperating income improves to less than -$500,000 in Q2 2026.
Worry ifOperating income worsens or stays below -$800,000 in Q2 2026.
Why it matters: The lease extension helps keep operations running smoothly. Delays could hurt cbdMD's growth.
Watch forThe warehouse lease extension is confirmed. It will start on October 1, 2026.
Also watch forThere are issues or delays with the warehouse lease extension.
Why it matters: A rebound in sector growth could benefit CBDMD. It would signal a stronger market environment.
Supportive ifSector revenue growth speeds up again, close to 9 percent.
Worry ifSector revenue growth slows down or stays the same.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$284 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $1,153 loss on $10,000 · 11.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,930 loss on $10,000 · 79.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Acquisitions can help grow the business and improve market share.
Supportive ifA new acquisition will increase market share or product options.
Worry ifNo new acquisitions announced in the next six months.
Why it matters: How the company uses its money is important due to new financial needs.
Worry ifManagement has a clear plan to handle new financial needs and boost cash flow.
Less concerning ifNo updates or unclear plans on capital use during ongoing losses is a concern.
Why it matters: Revenue growth from Twinlab will show if cbdMD's income is more diverse.
Supportive ifCombined revenue from Twinlab brands is over $30 million in the first full quarter.
Worry ifCombined revenue from Twinlab brands is below $30 million in the first full quarter.
Why it matters: New compensation plans can help retain talent and align interests. This is key for long-term success.
Supportive ifManagement gets good feedback or results from the new pay plans.
Worry ifBad feedback or no clear results from the new pay plans.
Why it matters: Court approval is needed to finalize the acquisition. This will confirm cbdMD's growth strategy.
Supportive ifCourt approval granted for the Twinlab acquisition, allowing the deal to close.
Worry ifThe court denied approval. This stops the acquisition from closing.
Why it matters: Earnings will show if the company is getting better or facing more losses.
Watch forQ2 earnings show smaller operating losses than the last quarter.
Also watch forThe Q2 earnings report shows more operating losses. These losses are continuing.